ClinicalTrials.gg
CompletedNCT05710510RE-TOOLUpdated Oct 27, 2026

Rural Engagement in TelemedTeam for Options in Obesity Treatment Solutions

An interventional study of Local Care + Model and Team Care Model in Obesity and Obesity, Morbid, sponsored by University of Kansas Medical Center. Completed at 1 site in United States. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Primary conditionObesity, MorbidRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Morbid
Why
  1. The study's listed conditions name Obesity, Morbid, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Kansas Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Oct 27, 2026Now CompletedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
582
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 213 studies in Obesity, Morbid with a site in United States — 28 open to participants now, 36 under way, 1 of them phase 3. Obesity, Morbid · United States.

Enrollment
6th of 150
582 · median 39
Started
2023
with 8 others
No phase
107 of 213
15 open now
Registered
188th of 213
by date

Among the 213 studies in Obesity, Morbid with a site in United States, this one is the 6th largest by enrollment of the 150 interventional ones that give a count, is one of 9 that started in 2023, is one of 107 with no phase, and was the 188th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

28 of the 213 studies in Obesity, Morbid with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Obesity, Morbid with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare two methods for managing obesity in rural primary care patients. The first method includes quarterly 1:1 meetings with the participant and their primary care provider and the second includes a group lifestyle intervention over Zoom paired with quarterly team meetings with the participant, their primary care provider and their lifestyle coach, the coach joining via Zoom. Investigators will evaluate which method is best at helping participants lose weight over 18 months.

Read the detailed description

Obesity increases risk for 13 types of cancer and now affects over 40% of the U.S. adult population, with even higher prevalence among rural Americans. Rural residents often lack access to weight control programs and food and physical activity resources that promote healthy lifestyles, especially in small or remote rural areas. It is important for obesity treatment to be offered in rural primary care, yet local resources are often lacking. Medical management by a primary care provider (PCP) during behavioral weight loss is essential to address co-morbid medical conditions, evaluate obesogenic medications, and explore options for guideline-recommended pharmacotherapy and surgical treatment. This study is designed to enhance sustainable access to obesity treatment in rural communities by offering education to local providers on obesity management and integrating team-based care into an obesity treatment model through telemedicine.

The two methods of obesity treatment to be studied are:

  • Local Care + Arm: Quarterly clinic visits with the participants and their local primary care provider
  • Team Care Arm: An intensive group lifestyle intervention offered by a lifestyle coach via Zoom, paired with quarterly clinic visits with the participant, their local primary care provider and the lifestyle coach, the coach joining via telemedicine.

Participants will be in the study about 18 months. Participants in the Local Care + arm will be asked to complete 4 data collection visits and 6 quarterly clinic visits. Participants in the Team Care arm will be asked to complete 4 data collection visits, 30 counseling sessions and 6 quarterly clinic visits.

03

Conditions studied

  • Obesity
  • Obesity, Morbid

Browse trials for

Keywords

  • Weight loss
  • Weight management
  • Behavioral intervention
  • Medical management of obesity
  • Team care
04

In context

Obesity, Morbid Reclassified

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

This study's enrollment of 582 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.

Browse Obesity, Morbid studies →

Lead sponsor

University of Kansas Medical Center is the lead sponsor of 493 studies on the registry; 111 are open to participants now.

Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.

Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • : >= 30 kg/m2
  • Rural resident
  • English speaking
  • Physician clearance to participate
  • Able to walk without assistance
  • Seen at least once in their primary care clinic within the past year
  • Internet access or smart phone (to access smart scale for weight measurement)

Exclusion criteria

Exclusion Criteria:

  • History of myocardial infarction within last six months
  • History of stroke within last six months
  • History of new cancer diagnosis within last six months
  • History of bariatric surgery within the last two years
  • Pregnancy within last 6 months or planned within the next 18 months
  • Currently breastfeeding
  • End stage renal disease, currently on dialysis, or anticipated dialysis or renal transplant within the next 18 months
  • End stage liver disease, or anticipated liver transplant within the next 18 months
  • Currently enrolled or planning to enroll in another study where weight loss is targeted or weight fluctuation is expected
  • Currently planning to move outside of current provider area, or leave primary care clinic within the next 18 months
  • Another household member is already participating in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
582 participants (actual)

Study arms

  • Active comparator
    Local Care + Model

    Quarterly clinic visits with a local primary care provider

    Behavioral: Local Care + Model

  • Active comparator
    Team Care Model

    An intensive group lifestyle intervention led by a lifestyle coach via Zoom, paired with quarterly clinic visits with a local primary care provider and the lifestyle coach, the coach joining via telemedicine.

    Behavioral: Team Care Model

Interventions

  • BehavioralLocal Care + Model

    Local primary care providers receive training in medical management of obesity prior to the start of the participant intervention. Participants receive 6 quarterly clinic visits with their local primary care provider focused on medical management of obesity.

  • BehavioralTeam Care Model

    Local primary care providers receive training in medical management of obesity prior to the start of the participant intervention. Participants receive an intensive 18-month group lifestyle intervention (30 total sessions) led by a study lifestyle coach via Zoom, and 6 quarterly 1:1 visits via Zoom with their lifestyle coach. Participants also receive 6 quarterly clinic visits with their local primary care provider; the study lifestyle coach joins the visits via telemedicine. All three parties may meet via telemedicine if needed. The group lifestyle intervention is led by obesity treatment specialists with relevant graduate training and experience.

07

What researchers measure

Primary outcomes

  1. Percent weight loss at 18 months

    Mean percent weight loss at 18 months; unadjusted

    Time frame: 18 months

Secondary outcomes

  1. Percent weight loss at 6 months

    Mean percent weight loss at 6 months; unadjusted

    Time frame: 6 months

  2. Percent weight loss at 12 months

    Mean percent weight loss at 12 months; unadjusted

    Time frame: 12 months

  3. Weight loss (kg) at 6 months

    Mean weight loss (kg) at 6 months; unadjusted

    Time frame: 6 months

  4. Weight loss (kg) at 12 months

    Mean weight loss (kg) at 12 months; unadjusted

    Time frame: 12 months

  5. Weight loss (kg) at 18 months

    Mean weight loss (kg) at 18 months; unadjusted

    Time frame: 18 months

  6. Proportion achieving ≥5% weight loss at 6 months

    Proportion achieving ≥5% weight loss at 6 months; unadjusted

    Time frame: 6 months

  7. Proportion achieving ≥5% weight loss at 12 months

    Proportion achieving ≥5% weight loss at 12 months; unadjusted

    Time frame: 12 months

  8. Proportion achieving ≥5% weight loss at 18 months

    Proportion achieving ≥5% weight loss at 18 months; unadjusted

    Time frame: 18 months

  9. Proportion achieving ≥10% weight loss at 6 months

    Proportion achieving ≥10% weight loss at 6 months; unadjusted

    Time frame: 6 months

  10. Proportion achieving ≥10% weight loss at 12 months

    Proportion achieving ≥10% weight loss at 12 months; unadjusted

    Time frame: 12 months

  11. Proportion achieving ≥10% weight loss at 18 months

    Proportion achieving ≥10% weight loss at 18 months; unadjusted

    Time frame: 18 months

  12. Change in diet quality at 6 months

    Mean change in diet quality, measured by Rapid Eating Assessment for Participant--Shortened Version (REAPS) at 6 months; unadjusted. The REAPS estimates diet quality through 13 items which assess weekly eating habits. Possible scores range from 13 (worst diet quality) to 39 (best diet quality).

    Time frame: Baseline and 6 months

  13. Change in diet quality at 12 months

    Mean change in diet quality, measured by Rapid Eating Assessment for Participant--Shortened Version (REAPS) at 12 months; unadjusted. The REAPS estimates diet quality through 13 items which assess weekly eating habits. Possible scores range from 13 (worst diet quality) to 39 (best diet quality).

    Time frame: Baseline and 12 months

  14. Change in diet quality at 18 months

    Mean change in diet quality, measured by Rapid Eating Assessment for Participant--Shortened Version (REAPS) at 18 months; unadjusted. The REAPS estimates diet quality through 13 items which assess weekly eating habits. Possible scores range from 13 (worst diet quality) to 39 (best diet quality).

    Time frame: Baseline and 18 months

  15. Change in physical activity at 6 months

    Mean change in MET-HOURS per week measured by Modifiable Activity Questionnaire (MAQ) at 6 months; unadjusted. The MAQ will be used to measure participants' leisure-time physical activity over the past 7 days. Leisure-time physical activity will be calculated as the Metabolic Equivalent of Task (MET) hours per week (MET-hr/week) and estimated by multiplying time (in hours) spent in an activity by the activities estimated MET and summing across all activities.

    Time frame: Baseline and 6 months

  16. Change in physical activity at 12 months

    Mean change in MET-HOURS per week measured by Modifiable Activity Questionnaire (MAQ) at 12 months; unadjusted. The MAQ will be used to measure participants' leisure-time physical activity over the past 7 days. Leisure-time physical activity will be calculated as the Metabolic Equivalent of Task (MET) hours per week (MET-hr/week) and estimated by multiplying time (in hours) spent in an activity by the activities estimated MET and summing across all activities.

    Time frame: Baseline and 12 months

  17. Change in physical activity at 18 months

    Mean change in MET-HOURS per week measured by Modifiable Activity Questionnaire (MAQ) at 18 months; unadjusted. The MAQ will be used to measure participants' leisure-time physical activity over the past 7 days. Leisure-time physical activity will be calculated as the Metabolic Equivalent of Task (MET) hours per week (MET-hr/week) and estimated by multiplying time (in hours) spent in an activity by the activities estimated MET and summing across all activities.

    Time frame: Baseline and 18 months

  18. Change in physical quality of life at 6 months

    Mean change in physical quality of life, measured by SF-12 at 6 months; unadjusted. The Short Form Health Survey (SF-12) is a general quality of life measure with a physical functioning summary score. Scores range from 0 to 100 with higher scores representing better functioning.

    Time frame: Baseline and 6 months

  19. Change in physical quality of life at 12 months

    Mean change in physical quality of life, measured by SF-12 at 12 months; unadjusted. The Short Form Health Survey (SF-12) is a general quality of life measure with a physical functioning summary score. Scores range from 0 to 100 with higher scores representing better functioning.

    Time frame: Baseline and 12 months

  20. Change in physical quality of life at 18 months

    Mean change in physical quality of life, measured by SF-12 at 18 months; unadjusted. The Short Form Health Survey (SF-12) is a general quality of life measure with a physical functioning summary score. Scores range from 0 to 100 with higher scores representing better functioning.

    Time frame: Baseline and 18 months

  21. Change in mental quality of life at 6 months

    Mean change in mental quality of life, measured by SF-12 at 6 months; unadjusted. The Short Form Health Survey (SF-12) is a general quality of life measure with a mental functioning summary score. Scores range from 0 to 100 with higher scores representing better functioning.

    Time frame: Baseline and 6 months

  22. Change in mental quality of life at 12 months

    Mean change in mental quality of life, measured by SF-12 at 12 months; unadjusted. The Short Form Health Survey (SF-12) is a general quality of life measure with a mental functioning summary score. Scores range from 0 to 100 with higher scores representing better functioning.

    Time frame: Baseline and 12 months

  23. Change in mental quality of life at 18 months

    Mean change in mental quality of life, measured by SF-12 at 18 months; unadjusted. The Short Form Health Survey (SF-12) is a general quality of life measure with a mental functioning summary score. Scores range from 0 to 100 with higher scores representing better functioning.

    Time frame: Baseline and 18 months

  24. Change in weight-related quality of life at 6 months

    Mean change in total quality of life, measured by Impact of Weight on Quality of Life-Lite (IWQOL-L) at 6 months; unadjusted. The IWQOL-L measure consists of a total score and five subscales--physical function, self-esteem, sexual life, public distress, and work. The total score ranges from 0 to 100 with higher scores indicating better quality of life.

    Time frame: Baseline and 6 months

  25. Change in weight-related quality of life at 12 months

    Mean change in total quality of life, measured by Impact of Weight on Quality of Life-Lite (IWQOL-L) at 12 months; unadjusted. The IWQOL-L measure consists of a total score and five subscales--physical function, self-esteem, sexual life, public distress, and work. The total score ranges from 0 to 100 with higher scores indicating better quality of life.

    Time frame: Baseline and 12 months

  26. Change in weight-related quality of life at 18 months

    Mean change in total quality of life, measured by Impact of Weight on Quality of Life-Lite (IWQOL-L) at 18 months; unadjusted. The IWQOL-L measure consists of a total score and five subscales--physical function, self-esteem, sexual life, public distress, and work. The total score ranges from 0 to 100 with higher scores indicating better quality of life.

    Time frame: Baseline and 18 months

08

Study locations

1 site
  • University of Kansas Medical Center
    Kansas City, Missouri 66160, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — A clean, de-identified copy of the final dataset will be created within 30 days of primary outcome paper publication. Data will be made available to researchers upon email request to the Principal Investigator. We will convert date of birth to age, and other identifiers (e.g, address, zip code, state) will be removed. Data and associated documentation will be made available to users under a data-sharing agreement that provides for: (1) a commitment to use the data solely for research purposes and to not identify individual participants during use or publication; (2) a commitment to secure the data using appropriate computer technology upon receipt; and (3) a commitment to destroy or return the data to the KU Medical Center after analyses are completed. Data will be saved as SAS or SPSS files and provided to requesters via KUMC's Secure File Transfer service. A copy of our analytic code used to generate our primary outcomes paper(s) will be made available on request in the same fashion.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Within 30 days of publication of the primary outcome paper

Access criteria: upon email request to the Principal Investigator

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Sep 2026, 42 months.

Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's 42 months is above that.

Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2022
First posted
Feb 2, 2023
StartActual
Mar 10, 2023
Primary completionActual
Sep 21, 2026was Oct 2026
CompletionActual
Sep 21, 2026was Oct 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 27, 2026
Primary completion
Oct 27, 2026→Sep 21, 2026 (actual)
Oct 27, 2026
Study completion
Oct 27, 2026→Sep 21, 2026 (actual)
Oct 27, 2026
Enrollment
560 (estimated)→582 (actual)
Oct 27, 2026
Documents
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Active, not recruiting→Completed
    Documents Informed consent form ↗ posted
    Primary completion Oct 27, 2026→Sep 21, 2026 (now actual)
    Study completion Oct 27, 2026→Sep 21, 2026 (now actual)
    Enrollment 560 (estimated)→582 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05710510
Responsible party
Sponsor
First posted
Feb 2, 2023
Start date
Mar 10, 2023
Primary completion
Sep 21, 2026
Completion
Sep 21, 2026
Last update
Oct 27, 2026

Study contacts

Christie Befort, PhD
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion